Corcept Therapeutics Incorporated
CORT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $675 | $482 | $402 | $366 |
| % Growth | 39.9% | 20% | 9.8% | – |
| Cost of Goods Sold | $11 | $6 | $5 | $5 |
| Gross Profit | $664 | $476 | $396 | $361 |
| % Margin | 98.4% | 98.7% | 98.7% | 98.6% |
| R&D Expenses | $247 | $184 | $131 | $114 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $280 | $184 | $153 | $122 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $527 | $369 | $284 | $236 |
| Operating Income | $137 | $107 | $113 | $124 |
| % Margin | 20.3% | 22.2% | 28% | 34% |
| Other Income/Exp. Net | $25 | $17 | $4 | $1 |
| Pre-Tax Income | $161 | $125 | $116 | $125 |
| Tax Expense | $20 | $18 | $15 | $12 |
| Net Income | $140 | $106 | $101 | $113 |
| % Margin | 20.7% | 22% | 25.2% | 30.7% |
| EPS | 1.35 | 1.02 | 0.95 | 0.97 |
| % Growth | 32.4% | 7.4% | -2.1% | – |
| EPS Diluted | 1.23 | 0.94 | 0.87 | 0.89 |
| Weighted Avg Shares Out | 103 | 104 | 107 | 116 |
| Weighted Avg Shares Out Dil | 113 | 112 | 116 | 126 |
| Supplemental Information | – | – | – | – |
| Interest Income | $25 | $17 | $4 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $3 |
| EBITDA | $138 | $108 | $114 | $128 |
| % Margin | 20.5% | 22.5% | 28.3% | 35% |